Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Wearables Could Revolutionize Pregnancy Monitoring and Detect Abnormalities

By HospiMedica International staff writers
Posted on 18 Sep 2025

Pregnancy complications such as miscarriage and preterm birth remain major risks to maternal and child health, especially in the United States, where more than 2 million women live in maternal care deserts. More...

Current monitoring methods rely on clinic visits and invasive testing, which can delay detection of adverse outcomes. Now, wearable devices could track physiological patterns that correlate with hormonal changes, offering earlier, more accessible pregnancy monitoring.

Scientists at Scripps Research (La Jolla, CA, USA) have found preliminary evidence suggesting that common wearable devices could remotely monitor pregnancy-related health changes by tracking physiological patterns—like heart rate—that correlate with hormonal fluctuations. Using the PowerMom platform, over 5,600 participants were enrolled, with 108 providing continuous data from three months before pregnancy through six months postpartum. The system analyzed heart rate, sleep, and activity patterns, aligning them with key hormones such as estrogen, progesterone, and hCG.

The analysis revealed that heart rate dropped during weeks five to nine of early pregnancy before steadily rising, peaking at 9.4 beats per minute above baseline prior to delivery, then declining postpartum. These physiological patterns correlated strongly with published hormone data, demonstrating predictive models for pregnancy progression. The findings, published in Lancet eBioMedicine, also showed differences in heart rate patterns for pregnancies ending in miscarriage or stillbirth compared to healthy pregnancies.

The study highlights how wearables could transform maternal healthcare by turning consumer devices into medical monitoring tools. This could provide continuous oversight for women in underserved areas and improve early detection of adverse outcomes like gestational diabetes or preeclampsia. Researchers plan to expand the analysis to include diverse demographic groups and to collect blood samples alongside wearable data to validate hormone-heart rate associations for clinical use.

“Wearable devices offer a unique opportunity to develop innovative solutions that address the high number of adverse pregnancy outcomes in the U.S.,” says co-senior author Giorgio Quer. “Our results show that signals collected via wearable sensors follow the expected changes in hormone levels and can detect unique patterns specific to live birth pregnancies, potentially allowing the monitoring of maternal health throughout the pregnancy and postpartum.”

Related Links:
Scripps Research


Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
Syringes
Prefilled Saline Flush Syringes
IV Therapy Cart
Avalo I.V Therapy Cart
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.